{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:31:23Z","timestamp":1790731883082,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1016\/j.clinthera.2010.06.019","type":"journal-article","created":{"date-parts":[[2010,8,5]],"date-time":"2010-08-05T08:59:22Z","timestamp":1280998762000},"page":"1234-1251","source":"Crossref","is-referenced-by-count":186,"title":["Effectiveness and tolerability of high-dose (23 mg\/d) versus standard-dose (10 mg\/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study"],"prefix":"10.1016","volume":"32","clinical-trial-number":[{"clinical-trial-number":"nct00478205","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Martin R.","family":"Farlow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Salloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre N.","family":"Tariot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Yardley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret L.","family":"Moline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elimor","family":"Brand-Schieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Satlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2010.06.019_bib1","series-title":"Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)","year":"1994"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2010.06.019_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1017\/S1041610297004675","article-title":"Diagnosis of Alzheimer's disease. Report of an International Psychogeriatric Association Special Meeting Work Group under the cosponsorship of Alzheimer's Disease International, the European Federation of Neurological Societies, the World Health Organization, and the World Psychiatric Association","volume":"9","author":"Reisberg","year":"1997","journal-title":"Int Psychogeriatr."},{"key":"10.1016\/j.clinthera.2010.06.019_bib4","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2165\/00003088-200241100-00003","article-title":"Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors","volume":"41","author":"Jann","year":"2002","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.clinthera.2010.06.019_bib5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jama.291.3.317","article-title":"Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial","volume":"291","author":"Tariot","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2010.06.019_bib6","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1212\/WNL.57.4.613","article-title":"A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease [published correction appears in Neurology. 2001;57:2153]","volume":"57","author":"Feldman","year":"2001","journal-title":"Neurology."},{"key":"10.1016\/j.clinthera.2010.06.019_bib7","first-page":"417","article-title":"Realistic expectations for treatment success in Alzheimer's disease","volume":"10","author":"Geldmacher","year":"2006","journal-title":"J Nutr Health Aging."},{"key":"10.1016\/j.clinthera.2010.06.019_bib8","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0140-6736(06)68350-5","article-title":"Donepezil in patients with severe Alzheimer's disease: Double-blind, parallel-group, placebo-controlled study [published corrections appear in Lancet. 2006;386:1650 and Lancet. 2006;367: 1980]","volume":"367","author":"Winblad","year":"2006","journal-title":"Lancet."},{"key":"10.1016\/j.clinthera.2010.06.019_bib9","first-page":"22","article-title":"Combination drug therapy for Alzheimer's disease: What is evidence-based, and what is not?","volume":"60","author":"Xiong","year":"2005","journal-title":"Geriatrics."},{"key":"10.1016\/j.clinthera.2010.06.019_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.17925\/USN.2008.04.01.31","article-title":"Combination therapies for treating Alzheimer's disease","volume":"4","author":"Tariot","year":"2008","journal-title":"US Neurology."},{"key":"10.1016\/j.clinthera.2010.06.019_bib11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1101\/lm.69204","article-title":"The cholinergic lesion of Alzheimer's disease: Pivotal factor or side show?","volume":"11","author":"Mesulam","year":"2004","journal-title":"Learn Mem."},{"key":"10.1016\/j.clinthera.2010.06.019_bib12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0197-4580(00)00090-7","article-title":"Choline acetyltrans-ferase activity and cognitive domain scores of Alzheimer's patients","volume":"21","author":"Pappas","year":"2000","journal-title":"Neurobiol Aging."},{"key":"10.1016\/j.clinthera.2010.06.019_bib13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/00023210-200115050-00004","article-title":"Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease","volume":"15","author":"Imbimbo","year":"2001","journal-title":"CNS Drugs."},{"key":"10.1016\/j.clinthera.2010.06.019_bib14","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1093\/ajhp\/54.24.2805","article-title":"Donepezil: An anticholinesterase inhibitor for Alzheimer's disease","volume":"54","author":"Shintani","year":"1997","journal-title":"Am J Health Syst Pharm."},{"key":"10.1016\/j.clinthera.2010.06.019_bib15","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/1531-8249(200009)48:3<391::AID-ANA17>3.0.CO;2-H","article-title":"Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex","volume":"48","author":"Kuhl","year":"2000","journal-title":"Ann Neurol."},{"key":"10.1016\/j.clinthera.2010.06.019_bib16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/jnnp.2004.038729","article-title":"Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease","volume":"76","author":"Bohnen","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1016\/j.clinthera.2010.06.019_bib17","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res."},{"key":"10.1016\/j.clinthera.2010.06.019_bib18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1479-8301.2009.00291.x","article-title":"Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan","volume":"9","author":"Nozawa","year":"2009","journal-title":"Psychogeriatrics."},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2010.06.019_bib19","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1212\/WNL.65.6_suppl_3.S1","article-title":"Moderate to severe Alzheimer disease: Definition and clinical relevance","volume":"65","author":"Farlow","year":"2005","journal-title":"Neurology."},{"key":"10.1016\/j.clinthera.2010.06.019_bib20","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology."},{"key":"10.1016\/j.clinthera.2010.06.019_bib21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/archneur.1994.00540130067012","article-title":"Severe impairment battery. A neuropsychological test for severely demented patients","volume":"51","author":"Panisset","year":"1994","journal-title":"Arch Neurol."},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2010.06.019_bib22","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1097\/00002093-199700112-00008","article-title":"The severe impairment battery: Concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study","volume":"11","author":"Schmitt","year":"1997","journal-title":"Alzheimer Dis Assoc Disord."},{"key":"10.1016\/j.clinthera.2010.06.019_bib23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0006-3223(88)90038-8","article-title":"Cornell Scale for Depression in Dementia","volume":"23","author":"Alexopoulos","year":"1988","journal-title":"Biol Psychiatry."},{"key":"10.1016\/j.clinthera.2010.06.019_bib24","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/014662167700100306","article-title":"The CES-D Scale: A Self-Report Depression Scale for Research in the General Population","volume":"1","author":"Radloff","year":"1977","journal-title":"Appl Psychol Meas."},{"key":"10.1016\/j.clinthera.2010.06.019_bib25","series-title":"Physicians' Desk Reference","year":"2010"},{"key":"10.1016\/j.clinthera.2010.06.019_bib26","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1017\/S1041610200006505","article-title":"Qualitative analysis of the clinician interview-based impression of change (Plus): Methodological issues and implications for clinical research","volume":"12","author":"Joffres","year":"2000","journal-title":"Int Psychogeriatr."},{"key":"10.1016\/j.clinthera.2010.06.019_bib27_1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1017\/S1041610296002645","article-title":"Clinical global impressions in Alzheimer's clinical trials","volume":"8","author":"Schneider","year":"1996","journal-title":"Int Psychogeriatr."},{"key":"10.1016\/j.clinthera.2010.06.019_bib27_2","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1017\/S1041610296002645","article-title":"Clinical global impressions in Alzheimer's clinical trials","volume":"8","author":"Schneider","year":"1996","journal-title":"Int Psychogeriatr."},{"key":"10.1016\/j.clinthera.2010.06.019_bib28","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1017\/S1355617705050502","article-title":"Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease","volume":"11","author":"Galasko","year":"2005","journal-title":"J Int Neuropsychol Soc."},{"key":"10.1016\/j.clinthera.2010.06.019_bib29","series-title":"Pharmaceutical Statistics Using SAS: A Practical Guide","author":"Dmitrienko","year":"2007"},{"key":"10.1016\/j.clinthera.2010.06.019_bib30","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/(SICI)1097-0258(19980815\/30)17:15\/16<1863::AID-SIM989>3.0.CO;2-M","article-title":"Issues for covariance analysis of dichotomous and ordered categorical data from randomized clinical trials and non-parametric strategies for addressing them","volume":"17","author":"Koch","year":"1998","journal-title":"Stat Med."},{"key":"10.1016\/j.clinthera.2010.06.019_bib31","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000086613","article-title":"Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease","volume":"20","author":"Brodaty","year":"2005","journal-title":"Dement Geriatr Cogn Disord."},{"key":"10.1016\/j.clinthera.2010.06.019_bib33","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/j.1532-5415.2004.52303.x","article-title":"Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease","volume":"52","author":"Galasko","year":"2004","journal-title":"J Am Geriatr Soc."},{"key":"10.1016\/j.clinthera.2010.06.019_bib34","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/089198870001300402","article-title":"Review of outcome measurement instruments in Alzheimer's disease drug trials: Psychometric properties of functional and quality of life scales","volume":"13","author":"Demers","year":"2000","journal-title":"J Geriatr Psychiatry Neurol."},{"key":"10.1016\/j.clinthera.2010.06.019_bib35","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1212\/01.wnl.0000266627.96040.5a","article-title":"Donepezil preserves cognition and global function in patients with severe Alzheimer's disease","volume":"69","author":"Black","year":"2007","journal-title":"Neurology."},{"key":"10.1016\/j.clinthera.2010.06.019_bib36","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000122961","article-title":"Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: Results from a 24-week, double-blind, placebocontrolled, randomized trial","volume":"25","author":"Homma","year":"2008","journal-title":"Dement Geriatr Cogn Disord."},{"key":"10.1016\/j.clinthera.2010.06.019_bib37","first-page":"330","article-title":"Consensus statement on dementia of Alzheimer type in the severe stage","volume":"9","author":"Vellas","year":"2005","journal-title":"J Nutr Health Aging."},{"key":"10.1016\/j.clinthera.2010.06.019_bib38","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/gps.1133","article-title":"Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: A meta-analysis of individual patient data from randomised controlled trials","volume":"19","author":"Whitehead","year":"2004","journal-title":"Int J Geriatr Psychiatry."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810002249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810002249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T10:00:45Z","timestamp":1559383245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291810002249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S0149291810002249"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2010.06.019","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}